Adaptimmune Therapeutics (ADAP) Priced

Developing cancer immunotherapies using genetically enhanced T-cell receptors.

Health Care - Biotechnology

IPO Performance
Latest Trade $4.06 0.00 (0.0%)
First Day Return -5.9%
Return from IPO -76.1%
 
Adaptimmune Therapeutics IPO News more
  • .
IPO Data
IPO File Date 04/06/2015
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) 191
 
IPO Data
IPO Date 05/05/2015
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
 
Underwriters
more
Business Overview
Developing cancer immunotherapies using genetically enhanced T-cell receptors.
Developing cancer immunotherapies using genetically enhanced T-cell receptors.
more
Company Data
Headquarters Abingdon, , United Kingdom
Founded 2008
Employees 106
Website www.adaptimmune.com
 

Performance vs. IPO Index (IPOUSA)